Silvana Canevari

11.4k total citations · 2 hit papers
227 papers, 8.7k citations indexed

About

Silvana Canevari is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Immunology. According to data from OpenAlex, Silvana Canevari has authored 227 papers receiving a total of 8.7k indexed citations (citations by other indexed papers that have themselves been cited), including 122 papers in Molecular Biology, 101 papers in Radiology, Nuclear Medicine and Imaging and 78 papers in Immunology. Recurrent topics in Silvana Canevari's work include Monoclonal and Polyclonal Antibodies Research (86 papers), Immunotherapy and Immune Responses (33 papers) and Glycosylation and Glycoproteins Research (29 papers). Silvana Canevari is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (86 papers), Immunotherapy and Immune Responses (33 papers) and Glycosylation and Glycoproteins Research (29 papers). Silvana Canevari collaborates with scholars based in Italy, United States and Germany. Silvana Canevari's co-authors include Delia Mezzanzanica, Maria I. Colnaghi, Silvia Miotti, Sylvie Ménard, Marina Bagnoli, Mariangela Figini, Antonella Tomassetti, Loris De Cecco, Elda Tagliabue and Egidio Iorio and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and Blood.

In The Last Decade

Silvana Canevari

224 papers receiving 8.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer

2006 984 citations Silvana Canevari et al. Clinical Cancer Research profile →
Targeting folate receptor alpha for cancer treatment

2016 348 citations Mariangela Figini, Silvana Canevari et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Silvana Canevari Italy	49	4.4k	3.2k	2.2k	1.9k	1.4k	227	8.7k
Donald J. Buchsbaum United States	51	4.8k 1.1×	3.4k 1.1×	1.4k 0.6×	1.9k 1.0×	1.2k 0.8×	281	9.2k
Raffaella Giavazzi Italy	57	6.2k 1.4×	4.0k 1.2×	1.4k 0.6×	696 0.4×	3.4k 2.4×	232	11.4k
Elda Tagliabue Italy	60	6.8k 1.6×	5.4k 1.7×	2.5k 1.1×	2.2k 1.2×	3.3k 2.3×	259	13.0k
Gerhard Moldenhauer Germany	52	3.4k 0.8×	2.7k 0.8×	2.9k 1.3×	1.8k 1.0×	860 0.6×	129	7.6k
Dorothee Herlyn United States	46	3.9k 0.9×	3.3k 1.0×	3.2k 1.4×	3.8k 2.0×	923 0.6×	154	8.4k
Joy Burchell United Kingdom	60	9.3k 2.1×	2.5k 0.8×	5.0k 2.2×	3.9k 2.1×	599 0.4×	131	12.2k
Edith M. Lord United States	41	1.8k 0.4×	2.2k 0.7×	2.5k 1.1×	990 0.5×	1.1k 0.7×	139	6.1k
Philip E. Thorpe United States	51	5.8k 1.3×	2.6k 0.8×	3.5k 1.5×	1.4k 0.7×	2.4k 1.7×	134	10.6k
Y. Gloria Meng United States	31	4.8k 1.1×	2.2k 0.7×	3.0k 1.3×	3.7k 2.0×	948 0.7×	48	8.6k
Germaine Fuh United States	45	5.0k 1.1×	1.9k 0.6×	1.3k 0.6×	2.0k 1.1×	1.2k 0.8×	62	7.5k

Countries citing papers authored by Silvana Canevari

Since Specialization

Citations

This map shows the geographic impact of Silvana Canevari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Silvana Canevari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Silvana Canevari more than expected).

Fields of papers citing papers by Silvana Canevari

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Silvana Canevari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Silvana Canevari. The network helps show where Silvana Canevari may publish in the future.

Co-authorship network of co-authors of Silvana Canevari

This figure shows the co-authorship network connecting the top 25 collaborators of Silvana Canevari. A scholar is included among the top collaborators of Silvana Canevari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Silvana Canevari. Silvana Canevari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Luison, Elena, Alessandro Desideri, Federico Iacovelli, et al.. (2021). Validity of Anti-PSMA ScFvD2B as a Theranostic Tool: A Narrative-Focused Review. Biomedicines. 9(12). 1870–1870. 4 indexed citations

Califano, Daniela, Daniela Russo, Giosuè Scognamiglio, et al.. (2020). Ovarian Cancer Translational Activity of the Multicenter Italian Trial in Ovarian Cancer (MITO) Group: Lessons Learned in 10 Years of Experience. Cells. 9(4). 903–903. 2 indexed citations

Cecco, Loris De, Carla Facco, Roberta Granata, et al.. (2019). A functional gene expression analysis in epithelial sinonasal cancer: Biology and clinical relevance behind three histological subtypes. Oral Oncology. 90. 94–101. 10 indexed citations

Siano, Marco, Vittoria Espeli, Nicolas Mach, et al.. (2018). Gene signatures and expression of miRNAs associated with efficacy of panitumumab in a head and neck cancer phase II trial. Oral Oncology. 82. 144–151. 10 indexed citations

Cecco, Loris De, Matteo Dugo, Gian Paolo Dagrada, et al.. (2018). The genomics of desmoplastic small round cell tumor reveals the deregulation of genes related to DNA damage response, epithelial–mesenchymal transition, and immune response. Cancer Communications. 38(1). 70–70. 23 indexed citations

Bossi, Paolo, Cristiana Bergamini, Marco Siano, et al.. (2016). Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab. Clinical Cancer Research. 22(15). 3961–3970. 53 indexed citations

Canevari, Silvana, et al.. (2010). Antibody Engineering as Opportunity for Selection and Optimization of Anti- HIV Therapeutic Agents. 2(1). 1 indexed citations

Spadaro, Francesca, Carlo Ramoni, Delia Mezzanzanica, et al.. (2008). Phosphatidylcholine-Specific Phospholipase C Activation in Epithelial Ovarian Cancer Cells. Cancer Research. 68(16). 6541–6549. 84 indexed citations

Castellano, Giancarlo, Grazia Malaponte, María Clorinda Mazzarino, et al.. (2008). Activation of the Osteopontin/Matrix Metalloproteinase-9 Pathway Correlates with Prostate Cancer Progression. Clinical Cancer Research. 14(22). 7470–7480. 98 indexed citations

10.

Moserle, Lidia, Stefano Indraccolo, Margherita Ghisi, et al.. (2008). The Side Population of Ovarian Cancer Cells Is a Primary Target of IFN-α Antitumor Effects. Cancer Research. 68(14). 5658–5668. 98 indexed citations

11.

Castellano, Giancarlo, James F. Reid, Paola Alberti, et al.. (2006). New Potential Ligand-Receptor Signaling Loops in Ovarian Cancer Identified in Multiple Gene Expression Studies. Cancer Research. 66(22). 10709–10719. 31 indexed citations

12.

Hasegawa, Kosei, Takafumi Nakamura, Mary Harvey, et al.. (2006). The Use of a Tropism-Modified Measles Virus in Folate Receptor–Targeted Virotherapy of Ovarian Cancer. Clinical Cancer Research. 12(20). 6170–6178. 73 indexed citations

13.

Turatti, Fabio, Mariangela Figini, Paola Alberti, et al.. (2004). Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. The Journal of Gene Medicine. 7(2). 158–170. 20 indexed citations

14.

Violini, Stefania, Sandra D’Ascenzo, Marina Bagnoli, et al.. (2004). Induction of a multifactorial resistance phenotype by high paclitaxel selective pressure in a human ovarian carcinoma cell line.. PubMed. 23(1). 83–91. 7 indexed citations

15.

Turatti, Fabio, Delia Mezzanzanica, Elena Nardini, et al.. (2001). Production and validation of the pharmacokinetics of a single-chain Fv fragment of the MGR6 antibody for targeting of tumors expressing HER-2. Cancer Immunology Immunotherapy. 49(12). 679–686. 8 indexed citations

16.

Miotti, Silvia, Donatella Negri, Olga Valota, et al.. (1999). Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. International Journal of Cancer. 84(1). 62–68. 35 indexed citations

17.

Canevari, Silvana, Delia Mezzanzanica, Alessandra Mazzoni, et al.. (1995). Bispecific Antibody Targeted T Cell Therapy of Ovarian Cancer: Clinical Results and Future Directions. Journal of Hematotherapy. 4(5). 423–427. 37 indexed citations

18.

Ferreri, Andrés J.M., et al.. (1992). Production and Characterization of a Monoclonal Antibody Against the Ribosome Inactivating Protein Alpha Sarcin. Hybridoma. 11(4). 437–446. 3 indexed citations

19.

Alzani, Rachele, Marco A. Pierotti, Sylvie Ménard, et al.. (1988). Monoclonal Antibodies Against NIH 3T3 Cells Transformed by Human Thyroid Carcinoma DNA. Hybridoma. 7(1). 7–18. 1 indexed citations

20.

Orlandi, Rosaria, Silvana Canevari, Flavio Leoni, et al.. (1986). Change in Binding Reactivity of an Anti-Tumor Monoclonal Antibody After the Introduction of 2-Pyridyl Disulphide Groups. Hybridoma. 5(1). 1–8. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact